PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.

ABSTRACT: Prostate cancer (PCa) is the second leading cause of cancer death for men in the United States. While organ-confined disease has reasonable expectation of cure, metastatic PCa is universally fatal upon recurrence during hormone therapy, a stage termed castration-resistant prostate cancer (CRPC). Until such time as molecularly defined subtypes can be identified and targeted using precision medicine, it is necessary to investigate new therapies that may apply to the CRPC population as a whole. The administration of ascorbate, more commonly known as ascorbic acid or Vitamin C, has proved lethal to and highly selective for a variety of cancer cell types. There are several mechanisms currently under investigation to explain how ascorbate exerts anti-cancer effects. A simplified model depicts as

SUBMITTER: Gordon N 

PROVIDER: S-EPMC10055378 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature